LEADS BIOLABS-B (09887) has announced that two preclinical pipeline research summaries will be presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The meeting is scheduled to take place from April 17 to April 22, 2026, at the San Diego Convention Center in California, USA.

The two studies highlight the company's innovative research in T-cell engager drug conjugates (TDCs) and dual-targeting ADCs. This further validates the synergistic R&D strategy of the company's three core proprietary technology platforms: the LeadsBodyTM (CD3 T-Cell Engager platform), the X-bodyTM (4-1BB Engager platform), and the TOPiKinecticsTM (ADC technology platform).

LBL-054 TDC is a first-in-class, CDH17-targeting bispecific ADC developed based on the company's proprietary antibody platform. It utilizes the proprietary TOPiKineticsTM linker-payload and combines the dual mechanisms of a T-cell engager and an ADC to deliver highly effective, low-toxicity precision treatment for gastrointestinal tumors, including colorectal, gastric, and pancreatic cancers.

LBL-061 is a novel EGFR/PD-L1 bispecific ADC conjugated via the company's proprietary TOPiKinecticsTM linker-payload platform. It integrates the tumor-targeting cytotoxicity of an ADC with immune activation, working synergistically to enhance anti-tumor effects. It is applicable for solid tumors such as head and neck cancer, non-small cell lung cancer, and nasopharyngeal carcinoma.